Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study in Healthy People to Measure How Different Doses of Verducatib Affect the Heart
Sponsor: Boehringer Ingelheim
Summary
The main objective of this trial is to evaluate the effects of verducatib in the range of therapeutic to supra-therapeutic exposures on the QT/QTc-interval and other ECG parameters
Official title: A Double-blind, Randomized, Placebo-controlled, Multiple-dose, Parallel Group Design Trial With Moxifloxacin as Positive Control in a Nested Crossover to Evaluate the Effects of Multiple Doses of Verducatib (BI 1291583) on Cardiac Safety Parameters in Healthy Male and Female Trial Participants
Key Details
Gender
All
Age Range
18 Years - 50 Years
Study Type
INTERVENTIONAL
Enrollment
56
Start Date
2026-08-20
Completion Date
2026-12-30
Last Updated
2026-09-09
Healthy Volunteers
Yes
Conditions
Interventions
Verducatib
Verducatib
Moxifloxacin
Moxifloxacin
Placebo resembling Verducatib
Placebo resembling Verducatib
Placebo resembling Moxifloxacin
Placebo resembling Moxifloxacin
Locations (1)
CRS Clinical Research Services Mannheim GmbH
Mannheim, Germany